Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm

(1) Background: Some severe COVID-19 patients develop hyperinflammatory cytokine storm syndrome (CSS). We assessed the efficacy of anakinra added to standard of care (SoC) in hospitalized COVID-19 CSS patients. (2) Methods: In this single-center, randomized, double-blind, placebo-controlled trial (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Lesley E., Khullar, Nitasha, Beukelman, Timothy, Chapleau, Chris, Kamath, Abhishek, Cron, Randy Q., Chatham, Walter Winn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612044/
https://www.ncbi.nlm.nih.gov/pubmed/37896812
http://dx.doi.org/10.3390/v15102036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612044/
https://www.ncbi.nlm.nih.gov/pubmed/37896812
http://dx.doi.org/10.3390/v15102036

Ejemplares similares